The effectiveness of the original anticonvulsant Galodif® — a GABAA receptor modulator for alcohol withdrawal syndrome

Abstract

BACKGROUND: The development of new drugs to improve the effectiveness of treatment and rehabilitation programs for patients suffering from addiction diseases, which are non-addictive and have a stimulating effect on detoxification processes in the body, can increase the effectiveness of therapy and reduce the cost of treatment. A deficiency of GABAergic inhibition in brain structures plays a leading role in the occurrence of paroxysmalness. The innovative anticonvulsant Galodif® (1-[(3-chlorophenyl)(phenyl)methyl]urea), a GABA_A receptor modulator, has low toxicity and hepatoprotective properties, which allows it to be recommended for use in the treatment of patients with alcohol dependence.

AIM: The aim of this study is to evaluation of the effectiveness of the use of the anticonvulsant drug galodif1 in complex therapy in patients with alcohol dependence with compulsive and paroxysmal disorders with pathological craving for alcohol when withdrawing of alcohol.

MATERIALS AND METHODS: A limited open-type clinical study of the therapeutic effectiveness of the innovative anticonvulsant galodif1 included 128 male patients (average age 38.3 ± 8.9 years) with a diagnosis of “Mental and behavioral disorders as a result of alcohol consumption, dependence syndrome” (F10.232) and “Mental and behavioral disorders as a result of alcohol consumption, withdrawal states” (F10.302). 68 patients received Galodif® 300 mg per day as an anticonvulsant for 21 days. 60 patients made up the comparison group, receiving carbamazepine at a dose of 400 mg per day.

RESULTS: The use of the anticonvulsant Galodif® in complex therapy of patients revealed: normothymoleptic activity of the drug; when assessing depression on the Hamilton Depression Rating Scale (HDRS), the average total score decreased from 28.3 ± 1.3 to 5.7 ± 1.9, and a reduction in unmotivated fear and anxiety was noted; vegetative stabilizing effect with a sympathicolytic component with normalization of heart rate; reduction of headaches; weakening or disappearance of pathological desire during withdrawal syndrome in 88% of cases, in the post-withdrawal state — in 57% of cases; taking the drug did not cause any unwanted side effects.

CONCLUSIONS: The use of the anticonvulsant Galodif®, which modulates GABA_A receptors, has low toxicity and detoxification properties and does not cause side effects, has been proposed as one of the modern pharmacotherapeutic approaches in the treatment of patients with alcohol dependence.

Keywords

alcoholism / anticonvulsant / Galodif / GABAA receptor / paroxysmal state / craving for alcohol / carbamazepine / relapse

References

[1] Anokhina IP. The basic biological mechanisms of substance use disorders. Journal of Addiction Problems. 2017;2–3:15–41.

[2] Анохина И.П. Основные биологические механизмы болезней зависимости от психоактивных веществ // Вопросы наркологии. 2017. № 2–3. С. 15–41.

[3] Lebedev AA, Lukashkova VV, Pshenichnaya AG, et al. Emotiogenic effects of antorex, a novel OX1R antagonist, on emotional manifestations of anxiety and compulsiveness in rats. Reviews on Clinical Pharmacology and Drug Therapy. 2023;21(2):151–158. DOI: 10.17816/RCF492319

[4] Лебедев А.А., Лукашкова В.В., Пшеничная А.Г., и др. Эмоциогенные эффекты анторекса, нового антагониста OX1R, на проявления тревожности и компульсивности у крыс // Обзоры клинической фармакологии и лекарственной терапии. 2023. Т. 21, № 2. С. 151–158. DOI: 10.17816/RCF492319

[5] Anokhina IP. New insight into the role of dopamine in the development of alcoholism. Journal of Addiction Problems. 2021;(6(201)):17–27. DOI: 10.47877/0234-0623_2021_06_17

[6] Анохина И.П. Новый взгляд на роль дофамина в механизмах формирования алкогольной зависимости // Вопросы наркологии. 2021. № 6(201). С. 17–27. DOI: 10.47877/0234-0623_2021_06_173

[7] Bohan NA, Semke VY. Comorbidity in narcology. Tomsk: Tomsk University Publishing House; 2009. 498 p. (In Russ.)

[8] Бохан Н.А., Семке В.Я. Коморбидность в наркологии. Томск: Издательство Томского университета, 2009, 498 с.

[9] Bohan NA, Mandel AI, Ivanova SA, et al. Old and new issues of addiction medicine in the context of interdisciplinary research. Journal of Addiction Problems. 2017;1:28–62.

[10] Бохан Н.А., Мандель А.И., Иванова С.А., и др. Старые и новые проблемы наркологии в контексте междисциплинарных исследований // Вопросы наркологии. 2017. № 1. С. 28–62.

[11] Kibitov AO, Shamakina IYu. Biological research in addiction medicine: current state of the art and future development. Journal of Addiction Problems. 2021;6(201):6–16. DOI: 10.47877/0234-0623_2021_06_6

[12] Кибитов А.О., Шамакина И.Ю. Биологические исследования в наркологии: современное состояние и перспективы развития // Вопросы наркологии. 2021. Т. 201, № 6. C. 6–16. DOI: 10.47877/0234-0623_2021_06_6

[13] Krupitsky EM, Rudenko AA, Tsoi MV, et al. The relationship between the craving for alcohol and relapse of the disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2007;107(S1):32–36. (In Russ.)

[14] Крупицкий Е.М., Руденко А.А., Цой М.В., и др. Связь патологического влечения к алкоголю у больных алкоголизмом в ремиссии с рецидивом заболевания // Журнал неврологии и психиатрии им. С.С. Корсакова — Алкоголизм. Приложение к журналу. 2007. Т. 7, № 1 С. 32–36.

[15] Everitt BJ, Robbins TW. Drug addiction: updating actions to habits to compulsions ten years on. Annu Rev Psychol. 2016;67:23–50. DOI: 10.1146/annurev-psych-122414-033457

[16] Everitt B.J., Robbins T.W. Drug addiction: updating actions to habits to compulsions ten years on // Annu Rev Psychol. 2016. Vol. 67. P. 23–50. DOI: 10.1146/annurev-psych-122414-033457

[17] Koob GF, Volkow ND. Neurocircuitry of addiction. Neuropsychopharmacology. 2010;35(1):217–238. DOI: 10.1038/npp.2009.110

[18] Koob G.F., Volkow N.D. Neurocircuitry of addiction // Neuropsychopharmacology. 2010. Vol. 35, Nо 1. P. 217–238. DOI: 10.1038/npp.2009.110

[19] Wolffgramm J, Heyne A. From controlled drug intake to loss of control: the irreversible development of drug addiction in the rat. Behav Brain Res. 1995;70(1):77–94. DOI: 10.1016/0166-4328(95)00131-c

[20] Wolffgramm J., Heyne A. From controlled drug intake to loss of control: the irreversible development of drug addiction in the rat // Behav Brain Res. 1995. Vol. 70, No. 1. P. 77–94. DOI: 10.1016/0166-4328(95)00131-c

[21] Augier E, Barbier E, Dulman RS, et al. A molecular mechanism for choosing alcohol over an alternative reward. Science. 2018;360(6395):1321–1326. DOI: 10.1126/science.aao1157

[22] Augier E., Barbier E., Dulman R.S., et al. A molecular mechanism for choosing alcohol over an alternative reward // Science. 2018. Vol. 360, No. 6395. P. 1321–1326. DOI: 10.1126/science.aao1157

[23] Seif T, Chang SJ, Simms JA, et al. Cortical activation of accumbens hyperpolarization-active NMDARs mediates aversion-resistant alcohol intake. Nat Neurosci. 2013;16(8):1094–1100. DOI: 10.1038/nn.3445

[24] Seif T., Chang S.J., Simms J.A., et al. Cortical activation of accumbens hyperpolarization-active NMDARs mediates aversion-resistant alcohol intake // Nat Neurosci. 2013. Vol. 16, Nо. 8. P. 1094–1100. DOI: 10.1038/nn.3445

[25] Domi E, Xu L, Toivainen S, et al. A neural substrate of compulsive alcohol use. Sci Adv. 2021;7(34):eabg9045. DOI: 10.1126/sciadv.abg9045

[26] Domi E., Xu L., Toivainen S., et al. A neural substrate of compulsive alcohol use // Sci Adv. 2021. Vol. 7, No. 34. P. eabg9045. DOI: 10.1126/sciadv.abg9045

[27] Ballenger JC, Post RM. Carbamazepine in alcohol withdrawal syndromes and schizophrenic psychoses. Psychopharmacology Bullutin. 1984;20(3):572–584.

[28] Ballenger J.C., Post R.M. Carbamazepine in alcohol withdrawal syndromes and schizophrenic psychoses // Psychopharmacology Bullutin. 1984. Vol. 20, No. 3. P. 572–584.

[29] Shushpanova TV, Solonsky AV, Shumilova SN, Bokhan NA. Formation of neuronal elements of the neuroimmune system of the human embryonic brain under the prenatal influence of alcohol. Siberian Journal of Psychiatry and Narcology. 2023;1(118):14–22. DOI: 10.26617/1810-3111-2023-1(118)-14-22

[30] Шушпанова Т.В., Солонский А.В., Шумилова С.Н., Бохан Н.А. Формирование нейрональных элементов нейроиммунной системы эмбрионального мозга человека при пренатальном влиянии алкоголя // Сибирский вестник психиатрии и наркологии. 2023. Т. 1, № 118. С. 14–22. DOI: 10.26617/1810-3111-2023-1(118)-14-22

[31] Shushpanova TV, Bokhan NA, Lebedeva VF, et al. The effect of chronic alcohol abuse on the benzodiazepine receptor system in various areas of the human brain. African Journal of Psychiatry (South Africa). 2016;19(3):1000365. DOI: 10.4172/2378-5756.1000365

[32] Shushpanova T.V., Bokhan N.A., Lebedeva V.F., et al. The effect of chronic alcohol abuse on the benzodiazepine receptor system in various areas of the human brain // African Journal of Psychiatry (South Africa). 2016. Vol. 19, Nо. 3. Р. 1000365. DOI: 10.4172/2378-5756.1000365

[33] Shushpanova TV, Solonskii AV, Shushpanova OV. Molecular-cellular targets of the pathogenetic action of ethanol in the human brain in ontogenesis and the possibility of targeted therapy aimed at correcting the effect of pathogenic factors. In: Drug addiction. Ed. by F. Zhao, co-ed. by M. Li. London, United Kingdom: Intech Open, 73–102 (2018). DOI: 10.5772/intechopen.70103

[34] Shushpanova T.V., Solonskii A.V., Shushpanova O.V. Molecular-cellular targets of the pathogenetic action of ethanol in the human brain in ontogenesis and the possibility of targeted therapy aimed at correcting the effect of pathogenic factors. In: Drug addiction. Ed. by F. Zhao, co-ed. by M. Li. London, United Kingdom: Intech Open, 73–102 (2018). DOI: 10.5772/intechopen.70103

[35] Volkow ND, Boyle M. Neuroscience of addiction: relevance to prevention and treatment. Am J Psychiatry. 2018;175(8):729–740. DOI: 10.1176/appi.ajp.2018.17101174

[36] Volkow N.D., Boyle M. Neuroscience of addiction: relevance to prevention and treatment // Am J Psychiatry. 2018. Vol. 175, Nо. 8. P. 729–740. DOI: 10.1176/appi.ajp.2018.17101174

[37] Shushpanova TV, Bokhan NA, Stankevich KS, et al. An innovatory GABA-A receptor modularor — microsomal cytochrome P-450 liver oxidase system activator in patients with alcoholism. Pharmaceutical Chemistry Journal. 2021;54(11):1093–1100. DOI: 10.1007/s11094-021-02327-x

[38] Шушпанова Т.В., Бохан Н.А., Станкевич К.С., и др. Инновационный модулятор ГАМК рецепторов — активатор микросомальной цитохром-Р450 оксидазной системы печени у больных алкоголизмом // Химико-фармацевтический журнал. 2020. Т. 54, № 11. С. 9–16. DOI: 10.30906/0023-1134-2020-54-11-9-16

[39] Fahlke C, Berggren U, Berglund KJ, et al. Neuroendocrine assessment of serotonergic, dopaminergic, and noradrenergic functions in alcohol-dependent individuals. Alcohol Clin Exp Res. 2012;36(1):97–103. DOI: 10.1111/j.1530-0277.2011.01598.x

[40] Fahlke C., Berggren U., Berglund K.J., et al. Neuroendocrine assessment of serotonergic, dopaminergic, and noradrenergic functions in alcohol-dependent individuals // Alcohol Clin Exp Res. 2012. Vol. 36, Nо. 1. P. 97–103. DOI: 10.1111/j.1530-0277.2011.01598.x

[41] Kroener S, Mulholland PJ, New NN, et al. Chronic alcohol exposure alters behavioral and synaptic plasticity of the rodent prefrontal cortex. PLoS One. 2012;7(5):e37541. DOI: 10.1371/journal.pone.0037541

[42] Kroener S., Mulholland P.J., New N.N., et al. Chronic alcohol exposure alters behavioral and synaptic plasticity of the rodent prefrontal cortex // PLoS One. 2012. Vol. 7, No. 5. P. e37541. DOI: 10.1371/journal.pone.0037541

[43] Nimitvilai S, Lopez MF, Mulholland PJ, Woodward JJ. Chronic intermittent ethanol exposure enhances the excitability and synaptic plasticity of lateral orbitofrontal cortex neurons and induces a tolerance to the acute inhibitory actions of ethanol. Neuropsychopharmacology. 2016;41(4):1112–1127. DOI: 10.1038/npp.2015.250

[44] Nimitvilai S., Lopez M.F, Mulholland P.J., Woodward J.J. Chronic intermittent ethanol exposure enhances the excitability and synaptic plasticity of lateral orbitofrontal cortex neurons and induces a tolerance to the acute inhibitory actions of ethanol // Neuropsychopharmacology. 2016. Vol. 41, No. 4. P. 1112–1127. DOI: 10.1038/npp.2015.250

[45] Olsen RW, Liang J. Role of GABAA receptors in alcohol use disorders suggested by chronic intermittent ethanol (CIE) rodent model. Mol Brain. 2017;10(1):45. DOI: 10.1186/s13041-017-0325-8

[46] Olsen R.W., Liang J. Role of GABAA receptors in alcohol use disorders suggested by chronic intermittent ethanol (CIE) rodent model // Mol Brain. 2017. Vol. 10, Nо. 1. P. 45. DOI: 10.1186/s13041-017-0325-8

[47] Osby U, Liljenberg J, Kockum I, et al. Genes and alcohol. Eur Psychiatry. 2010;25(5):281–283. DOI: 10.1016/j.eurpsy.2010.01.004

[48] Osby U., Liljenberg J., Kockum I., et al. Genes and alcohol // Eur Psychiatry. 2010. Vol. 25, Nо. 5. P. 281–283. DOI: 10.1016/j.eurpsy.2010.01.004

[49] Pascoli V, Hiver A, Van Zessen R, et al. Stochastic synaptic plasticity underlying compulsion in a model of addiction. Nature. 2018;564(7736):366–371. DOI: 10.1038/s41586-018-0789-4

[50] Pascoli V., Hiver A., Van Zessen R., et al. Stochastic synaptic plasticity underlying compulsion in a model of addiction // Nature. 2018. Vol. 564, No. 7736. P. 366–371. DOI: 10.1038/s41586-018-0789-4

[51] Roberto M, Varodayan FP. Synaptic targets: Chronic alcohol actions. Neuropharmacology. 2017;122:85–99. DOI: 10.1016/j.neuropharm

[52] Roberto M., Varodayan F.P. Synaptic targets: Chronic alcohol actions // Neuropharmacology. 2017. Vol. 122. P. 85–99. DOI: 10.1016/j.neuropharm

[53] Shushpanova TV, Solonskii AV. Synaptogenesis and the formation of benzodiazepinereceptors in the human brain in conditions of prenatal alcoholization. Neuroscience and Behavioral Physiology. 2013;43(4):423–430. DOI: 10.1007/s11055-013-9749-5

[54] Shushpanova T.V., Solonskii A.V. Synaptogenesis and the formation of benzodiazepinereceptors in the human brain in conditions of prenatal alcoholization // Neuroscience and Behavioral Physiology. 2013. Vol. 43, No. 4. P. 423–430. DOI: 10.1007/s11055-013-9749-5

[55] Shushpanova TV, Bokhan NA, Kuksenok VYu, et al. A novel urea derivative anticonvulsant: in vivo biological evaluation, radioreceptor analysis of GABAA receptors and molecular docking studies of enantiomers. Mendeleev Communications. 2023;33(4):546–549. DOI: 10.1016/j.mencom.2023.06.034

[56] Shushpanova T.V., Bokhan N.A., Kuksenok V.Yu., et al. A novel urea derivative anticonvulsant: in vivo biological evaluation, radioreceptor analysis of GABAA receptors and molecular docking studies of enantiomers // Mendeleev Communications. 2023. Vol. 33, No. 4. Р. 546–549. DOI: 10.1016/j.mencom.2023.06.034

[57] Vasilieva SN, Simutkin GG, Schastnyy ED, et al. Affective disorders in comorbidity with alcohol addiction: clinical and dynamic features, social adaptation level of patients. Bulletin of Siberian Medicine. 2020;19(1):29–35. DOI: 10.20538/1682-0363-2020-1-29-35

[58] Васильева С.Н., Симуткин Г.Г., Счастный Е.Д., и др. Аффективные расстройства при коморбидности с алкогольной зависимостью: клинико-динамические особенности, уровень социальной адаптации больных // Бюллетень сибирской медицины. 2020. Т. 19, № 1. С. 29–35. DOI: 10.20538/1682-0363-2020-1-29-35

[59] Gofman AG, Ponizovskiy PA. On comorbidity of depression and alcohol addiction. Journal of Addiction Problems. 2017;4–5:103–112.

[60] Гофман А.Г., Понизовский П.А. О сочетании депрессивных расстройств с зависимостью от алкоголя // Вопросы наркологии. 2017. № 4–5. С. 103–112.

[61] Kysel NI, Bedarev RY, Mandel AI, et al. Algorithm for personalized therapy of patients with alcoholism with comorbid disorders of the detoxifying function of the liver and cognitive disorders. Siberian Herald of Psychiatry and Addiction Psychiatry. 2022;117(4):33–43. DOI: 10.26617/1810-3111-2022-4(117)-33-43

[62] Кисель Н.И., Бедарев Р.И., Мандель А.И., и др. Алгоритм персонализированной терапии больных алкоголизмом с коморбидными нарушениями детоксицирующей функции печени и когнитивными расстройствами // Сибирский вестник психиатрии и наркологии. 2022. Т. 117, № 4. С. 33–43. DOI: DOI: 10.26617/1810-3111-2022-4(117)-33-43

[63] Krupitsky EM, Akhmetova EA, Asadullin AR. Pharmacogenetics of chemical addictions. V.M. Bekhterev Review of psychiatry and medical psychology. 2019;(4–1):12–20. DOI: 10.31363/2313-7053-2019-4-1-12-20

[64] Крупицкий Е.М., Ахметова Э.А., Асадуллин А.Р. Фармакогенетика химических зависимостей // Обозрение психиатрии и медицинской психологии имени В.М. Бехтерева. 2019. № 4–1. С. 12–20. DOI: 10.31363/2313-7053-2019-4-1-12-20

[65] Nikiforov IA, Nikiforov II, Aronov PV. Alcoholism and comorbid cerebral disorders: A review of literature. Profilakticheskaya Meditsina. 2015;18(3):47–54. (In Russ.) DOI: 10.17116/profmed201518347-54

[66] Никифоров И.А., Никифоров И.И., Аронов П.В. Алкогольная болезнь и коморбидные церебральные расстройства (обзор литературы) // Профилактическая медицина. 2015. № 3. С. 47–54. DOI: 10.17116/profmed201518347-54

[67] Bellos S, Skapinakis P, Rai D, et al. Cross-cultural patterns of the association between varying levels of alcohol consumption and the common mental disorders of depression and anxiety: secondary analysis of the WHO Collaborative Study on Psychological Problems in General Health Care. Drug Alcohol Depend. 2013;133(3):825–831. DOI: 10.1016/j.drugalcdep.2013.08.030

[68] Bellos S., Skapinakis P., Rai D., et al. Cross-cultural patterns of the association between varying levels of alcohol consumption and the common mental disorders of depression and anxiety: secondary analysis of the WHO Collaborative Study on Psychological Problems in General Health Care // Drug Alcohol Depend. 2013. Vol. 133, Nо 3. P. 825–831. DOI: 10.1016/j.drugalcdep.2013.08.030

[69] Addolorato G, Leggio L, Hopf FW, et al. Novel therapeutic strategies for alcohol and drug addiction: focus on GABA, ion channels and transcranial magnetic stimulation. Neuropsychopharmacology. 2012;37(1):163–177. DOI: 10.1038/npp.2011.216

[70] Addolorato G., Leggio L., Hopf F.W., Diana M., Bonci A. Novel therapeutic strategies for alcohol and drug addiction: focus on GABA, ion channels and transcranial magnetic stimulation // Neuropsychopharmacology. 2012. Vol. 37, Nо. 1. P. 163–177. DOI: 10.1038/npp.2011.216

[71] Kolik LG. Development of new pharmacologicak agents for the treatment of alcohol dependency with allowance fot individual features. Experimental and Clinical Pharmacology. 2021;84(2):53–58. DOI: 10.30906/0869-2092-2021-84-2-53-58

[72] Колик Л.Г. Разработка новых фармакологических средств для лечения алкогольной зависимости с учетом индивидуальных особенностей // Экспериментальная и клиническая фармакология. 2021. Т. 84, № 2. С. 53–58. DOI: 10.30906/0869-2092-2021-84-2-53-58

[73] Ballenger JC, Post RM. Kindling as a model for alcohol withdrawal syndromes. Br J Psychiatry. 1978;133:1–14. DOI: 10.1192/bjp.133.1.1

[74] Ballenger J.C., Post R.M. Kindling as a model for alcohol withdrawal syndromes // Br J Psychiatry. 1978. Vol. 133. Р. 1–14. DOI: 10.1192/bjp.133.1.1

[75] Heilig M, Augier E, Pfarr S, Sommer WH. Developing neuroscience-based treatments for alcohol addiction: A matter of choice? Transl Psychiatry. 2019;9(1):255. DOI: 10.1038/s41398-019-0591-6

[76] Heilig M., Augier E., Pfarr S., Sommer W.H. Developing neuroscience-based treatments for alcohol addiction: A matter of choice? // Transl Psychiatry. 2019. Vol. 9, Nо. 1. P. 255. DOI: 10.1038/s41398-019-0591-6

[77] Pati S, Saba K, Salvi SS, et al. Chronic postnatal chemogenetic activation of forebrain excitatory neurons evokes persistent changes in mood behavior. eLife. 2020;9:e56171.

[78] Pati S., Saba K., Salvi S.S., et al. Chronic postnatal chemogenetic activation of forebrain excitatory neurons evokes persistent changes in mood behavior // eLife. 2020. Vol. 9. P. e56171.

[79] Wagner FA, Anthony JC. From first drug use to drug dependence; developmental periods of risk for dependence upon marijuana, cocaine, and alcohol. Neuropsychopharmacology. 2002;26(4):479–488. DOI: 10.1016/S0893-133X(01)00367-0

[80] Wagner F.A., Anthony J.C. From first drug use to drug dependence; developmental periods of risk for dependence upon marijuana, cocaine, and alcohol // Neuropsychopharmacology. 2002. Vol. 26, Nо. 4. P. 479–488. DOI: 10.1016/S0893-133X(01)00367-0

[81] Renteria R, Baltz ET, Gremel CM. Chronic alcohol exposure disrupts top-down control over basal ganglia action selection to produce habits. Nat Commun. 2018;9(1):211. DOI: 10.1038/s41467-017-02615-9

[82] Renteria R., Baltz E.T., Gremel C.M. Chronic alcohol exposure disrupts top-down control over basal ganglia action selection to produce habits // Nat Commun. 2018. Vol. 9, No. 1. P. 211. DOI: 10.1038/s41467-017-02615-9

[83] Seif T, Chang SJ, Simms JA, et al. Cortical activation of accumbens hyperpolarization-active NMDARs mediates aversion-resistant alcohol intake. Nat Neurosci. 2013;16(8):1094–1100. DOI: 10.1038/nn.3445

[84] Seif T., Chang S.J., Simms J.A., et al. Cortical activation of accumbens hyperpolarization-active NMDARs mediates aversion-resistant alcohol intake // Nat Neurosci. 2013. Vol. 16, Nо. 8. P. 1094–1100. DOI: 10.1038/nn.3445

[85] Shushpanova TV, Novozheeva TP, Mandel AI, Knyazeva EM. Molecular targets of the action of innovative anticonvulsant galodif in the therapy of alcohol dependence. Siberian Herald of Psychiatry and addiction Psychiatry. 2018;(2):120–126. DOI: 10.26617/1810-3111-2018-2(99)-120-126

[86] Шушпанова Т.В., Новожеева Т.П., Мандель А.И., Князева Е.М. Молекулярные мишени действия инновационного антиконвульсанта галодиф в терапии алкогольной зависимости // Сибирский вестник психиатрии и наркологии. 2018. № 2. С. 120–126. DOI: 10.26617/1810-3111-2018-2(99)-120-126

[87] Morley KC, Perry CJ, Watt J, et al. New approved and emerging pharmacological approaches to alcohol use disorder: a review of clinical studies. Expert Opin Pharmacother. 2021;22(10):1291–1303. DOI: 10.1080/14656566.2021.1892641

[88] Morley K.C., Perry C.J., Watt J., et al. New approved and emerging pharmacological approaches to alcohol use disorder: a review of clinical studies // Expert Opin Pharmacother. 2021. Vol. 22, Nо. 10. P. 1291–1303. DOI: 10.1080/14656566.2021.1892641

[89] Shafie A, Mohammadi-Khanaposhtani V, Asadi M, et al. Novel fused 1,2,3-triazolo-benzodiazepine derivatives as potent anticonvulsant agents: design, synthesis, in vivo, and in silicoevaluations. Molecular Diversity. 2020;24:179–189. DOI: 10.1007/s11030-019-09940-9

[90] Shafie A., Mohammadi-Khanaposhtani V., Asadi M., et al. Novel fused 1,2,3-triazolo-benzodiazepine derivatives as potent anticonvulsant agents: design, synthesis, in vivo, and in silicoevaluations // Molecular Diversity. 2020. Vol. 24. P. 179–189. DOI: 10.1007/s11030-019-09940-9

[91] Markova EV, Savkin IV, Knyazheva MA, Shushpanova TV. Anticonvulsant with immunomodulating properties in alcoholism therapy: experimental study. Siberian Herald of Psychiatry and Addiction Psychiatry. 2020;106(1):14–22. DOI: 10.26617/1810-3111-2020-1(106)-14-22

[92] Маркова Е.В., Савкин И.В., Княжева М.А., Шушпанова Т.В. Антиконвульсант с иммуномодулирующими свойствами в терапии алкоголизма: экспериментальное исследование // Сибирский вестник психиатрии и наркологии. 2020. Т. 106, № 1. С. 14–22. DOI: 10.26617/1810-3111-2020-1(106)-14-22

[93] Patent RU2436573/12/20/2011. Semke VYa, Shushpanova TV, Novozheeva TP, et al. Method of rehabilitation of patients with alcoholism. (In Russ.)

[94] Патент на изобретение РФ № 2436573/ 20.12.2011. Семке В.Я., Шушпанова Т.В., Новожеева Т.П., и др. Способ реабилитации больных алкоголизмом.

[95] Altshuler VB, Cherednichenko NV. Quantitative assessment of the structure and dynamics of pathological attraction to alcohol. Journal of Addiction Problems. 1992;(3–4):14–17. (In Russ.)

[96] Альтшулер В.Б., Чередниченко Н.В. Количественная оценка структуры и динамики патологического влечения к алкоголю у больных алкоголизмом // Вопросы наркологии. 1992. № 3–4. С. 14–17.

[97] Spanagel R. Aberrant choice behavior in alcoholism. Science. 2018;360(6395):1298–1299. DOI: 10.1126/science.aau0668

[98] Spanagel R. Aberrant choice behavior in alcoholism // Science. 2018. Vol. 360, No. 6395. P. 1298–1299. DOI: 10.1126/science.aau0668

[99] Nechaev MO, Sychev DA, Zastrozhin MS, Grishina EA, et al. Anticonvulsants in narcological practice. Prospects for personalized use. Narcology. 2017;(9):103–116. DOI: 10.17116/profmed201518347-54

[100] Нечаев М.О., Сычев Д.А., Застрожин М.С., Гришина Е.А. и др. Противосудорожные средства в наркологической практике. Перспективы персонализированного применения // Наркология. 2017. № 9. С. 103–116. DOI: 10.17116/profmed201518347-54

[101] Sivolap YP. Alcoholism and modern methods of its treatment. Psychiatry and Psychopharmacotherapy. 2009;11(4):5–29. (In Russ.)

[102] Сиволап Ю.П. Алкоголизм и современные методы его лечения // Психиатрия и психофармакотерапия. 2009. Т. 11, № 4. С. 5–29.

[103] Seifert J, Peters E, Jahn K, et al. Treatment of alcohol withdrawal: chlormethiazole vs. carbamazepine and the effect on memory performance — a pilot study. Addict Biol. 2004;9(1):43–51. DOI: 10.1080/13556210410001674086

[104] Seifert J., Peters E., Jahn K., et al. Treatment of alcohol withdrawal: chlormethiazole vs. carbamazepine and the effect on memory performance — a pilot study // Addict Biol. 2004. Vol. 9, No. 1. P. 43–51. DOI: 10.1080/13556210410001674086

[105] Soyka M, Schmidt P, Franz M, et al. Treatment of alcohol withdrawal syndrome with a combination of tiapride/carbamazepine: results of a pooled analysis in 540 patients. Eur Arch Psychiatry Clin Neurosci. 2006;256(7):395–401. DOI: 10.1007/s00406-006-0644-8

[106] Soyka M., Schmidt P., Franz M., et al. Treatment of alcohol withdrawal syndrome with a combination of tiapride/carbamazepine: results of a pooled analysis in 540 patients // Eur Arch Psychiatry Clin Neurosci. 2006. Vol. 256, No. 7. P. 395–401. DOI: 10.1007/s00406-006-0644-8

[107] Altshuler VB, Kravchenko SL. Clinical studies of alcoholism as a source of therapeutic searches. Questions of Narcology. 2010;6: 34–43. (In Russ.)

[108] Альтшулер В.Б., Кравченко С.Л. Клинические исследования алкоголизма как источник терапевтических поисков // Вопросы наркологии. 2010, № 6. С. 34–43.

RIGHTS & PERMISSIONS

ECO-vector